The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 801–838 of 838
The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer
Mori, H., Akiyama, Y., Maeda, C., Kanematsu, A., Ashizawa, T., Yamashita, K., Miyata, H., Iizuka, A., Ikeya, T., Yasunaga, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04208-8
The BCG in situ study – novel techniques applied to a 100-year-old vaccine
Schaltz‐Buchholzer, F., Bæk, O., Singh, A., Cá, E., da Silva, I., Aaby, P., Benn, C. S., Kollmann, T. R., & Amenyogbe, N. (2025) · MethodsX · doi:10.1016/j.mex.2025.103712
Response-Based Immunotherapy in Melanoma
Bushara, O., Farooq, M. S., Vargas, G. M., & Karakousis, G. C. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.002
Russell, M., Emmett, L., Perić, B., Saw, R. P. M., Spillane, J. B., Vasquez, V., Neto, J. P. D., Moncrieff, M. D., Allan, C. P., van Leeuwen, B. L., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.111163
Boudriga, H., Charfi, J., Ezzine, A., Korbi, M., Hassine, I. B., Dardouri, T., Sfar, R., & Chatti, K. (2025) · F1000Research · doi:10.12688/f1000research.170621.1
Long, F., Lin, Z., Li, L., Ma, M., Lu, Z., Jing, L., Li, X., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.13710833
Tilsed, C. M., Morales, M. L. O., Zemek, R. M., Gordon, B. A., Piggott, M., Nowak, A. K., Fisher, S. A., Lake, R., & Lesterhuis, W. J. (2024) · Figshare · doi:10.6084/m9.figshare.25216824
Baars, M. J. D., Sinha, N., Amini, M., Pieterman-Bos, A., van Dam, S., Ganpat, M. M. P., Laclé, M. M., Oldenburg, B., & Vercoulen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14576348
Baars, M. J. D., Sinha, N., Amini, M., Pieterman-Bos, A., van Dam, S., Ganpat, M. M. P., Laclé, M. M., Oldenburg, B., & Vercoulen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14576351
Baars, M. J. D., Sinha, N., Amini, M., Pieterman-Bos, A., van Dam, S., Ganpat, M. M. P., Laclé, M. M., Oldenburg, B., & Vercoulen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14576342
Baars, M. J. D., Sinha, N., Amini, M., Pieterman-Bos, A., van Dam, S., Ganpat, M. M. P., Laclé, M. M., Oldenburg, B., & Vercoulen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14576345
Іmmunotherapy in perioperative treatment of oncological patients. Part ІI
Сорочан, П. П., Prokhach, N. E., Hromakova, I. S., Olkhovskyi, D. V., & Hromakova, I. А. (2025) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2025.498-508
Duarte-Bateman, D., Escandón, J. M., Shen, A., Chen, Y., Ko, J., Melenhorst, J. J., Tufaro, A. P., Kennedy, L. B., Isaacs, J. M., & Gastman, B. (2026) · Melanoma Research · doi:10.1097/cmr.0000000000001079
Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to ImmunotherapyPreprint
Ruta, A., Gray-Gaillard, E. F., Garcia, J. A., Huyer, L. D., Mathkour, Y., Cherry, C., Patatanian, M., Mejías, J. C., Maestas, D. R., Krishnan, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703323
From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma
Mokos, M., & Šitum, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16030147
Overview of RNA-sequencing and applications to neuro-oncology
Patel, H. M., Chaudhary, A., Venugopal, C., Singh, S. K., & Escudero, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00080-2
Neoadjuvante Therapie bei Hautkrebs: aktuelle Datenlage und Ausblicke
Daniello, L., Kleemann, J., & Schilling, B. (2026) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15968_g
Bergström, A., Nelson, A., Huibers, A. E., Cicek, E., Silverdal, Å., Johansson, M., Lundmark, K., Selling, J., Muszta, A., & Johansson, I. (2026) · Cancers · doi:10.3390/cancers18091400
Neoadjuvant Therapy for Melanoma
O'Connor, M. H., DeLaura, I. F., & Beasley, G. M. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.005
Lawless, A. R., Effiom, D. N., Burbano, A. V., Sharova, T., Otten, T. J., Basnet, M., Spurr, E., Shankar, T., Crespo, M. C., Czapla, J. A., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19814-8
Figueiredo, C. R., & Park, G. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1015805
PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective
Ding, Z., Xue, R., Jin, Q., Zhang, W., Wu, Y., & Xu, B. (2026) · iMetaMed · doi:10.1002/imm3.70045
TCR Repertoire: Metrics, Structure and Clinical Implementation
Zornikova, K. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015233
Evolving Landscape of Immunotherapy in Melanoma
Darwin, A. H., Dickerson, J. C., & Funchain, P. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01301
Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma
Amouzegar, A., Shaw, R., Tsai, K. K., Olson, D., & Gibney, G. T. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-520562
Chen, S., Wang, Y., Chen, J., Xie, W., Chen, J., Liao, G., Ren, X., Lei, K., Zhang, Y., Wang, S., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.06.010 · Cited by 1
Wang, X., Wang, Q., (2085), W. G., He, S., Xiong, D., Huang, Y., & Zou, B. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02748-w
Hu, H., Ng, A. H. C., & Lü, Y. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104825
PanoraOnc: A pan-cancer clinico-genomic AI model for transferable outcome predictionsPreprint
Schuerch, M., Geisberg, J., Flower, C. T., Bektaş, A. B., McDonald, T. O., Mishra, S., Graser, C. J., Altreuter, J., Ananda, G., Boland, G. M., et al. (2026) · medRxiv · doi:10.64898/2026.08.17.26354679
Shi, J., & Chen, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919497
Liu, Z., Song, X., Chen, W.-S., Dhingra, S., He, J., He, L., Chen, C., Balasi, J. A., Sayegh, Z., Segura, C. M. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.12.751186
Self-citationReal-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series
Ren, Y., Guo, X., Xing, H., Kang, X., Liang, T., Shi, Y., Yao, B., Ma, W., & Wang, Y. (2026) · Cancers · doi:10.3390/cancers18193122
Long, G. V., da Silva, I. P., Perry, K. J., Romano, J., Lo, S., Grover, P., Ascierto, P. A., Amaria, R. N., Hieken, T. J., Robert, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04677-z
Self-citationMilian, L. M., Geindreau, M., Pignol, C., & Végran, F. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00612-3
Rawson, R. V., Burton, E. M., & Tetzlaff, M. T. (2026) · Histopathology · doi:10.1111/his.70281
Self-citationQin, R. Z., Abberger, H., Man, G., Broomfield, B. J., Williams, B. E., Tan, C. W., Duckworth, B. C., Jenkins, M. R., Geoghegan, N. D., Rogers, K. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.758663
Wang, Q., Liu, Y., Zuo, L., Gao, S., Chen, J., Xue, L., Li, P., Lei, X., Lin, J., Han, Y., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2744077
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
